NCT07623473Recruiting
Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation
NIMBLE | Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation
Source: ClinicalTrials.gov · Last updated 3 Jun 2026
Brief summary (registry, in English)
The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule. Each blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1800 (estimated)
- First submitted
- 29 May 2026
- Start date
- 22 May 2024
- Primary completion date
- 1 Feb 2028
- Lead sponsor
- Herlev and Gentofte Hospital
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT07623473
What you commit to
- Study type: Observational
- Planned participants: 1800
- From 22 May 2024 to the primary completion date, 1 Feb 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active cancer, excluding non-melanoma skin cancer
Other
- Comorbidities that exclude the patient from clinical follow-up and final diagnosis
Who the study is looking for
- Patients with a newly detected IPN suspected of lung cancer referred to the infiltrate unit
- Having signed informed consent
Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gentofte Hospital Coordinator of this site? Confirm its status | Gentofte Municipality | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.